WEBULL
News
BMRN
59.45
+0.03%
0.02
BioMarin Acquiring Amicus -- Both Great Companies, Only One Worth Buying Now
Seeking Alpha · 12/30/2025 21:39
Weekly Report: what happened at BMRN last week (1222-1226)?
Weekly Report · 12/29/2025 10:33
Rocket Lab, Micron, And CoreWeave Are Among the Top 10 Large-Cap Gainers Last Week (Dec. 22-Dec. 26): Are the Others in Your Portfolio?
Benzinga · 12/28/2025 13:00
BioMarin Pharmaceuticals: Amicus Transforms Business Case Overnight
Seeking Alpha · 12/26/2025 22:07
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2025 Update
Seeking Alpha · 12/26/2025 02:40
Is BioMarin a Bargain After Recent 16.1% Jump and Strong DCF Outlook?
Simply Wall St · 12/25/2025 21:22
Silver Breaks Above $70, Novo Nordisk Soars 9% On Obesity Pill Approval: What's Moving Markets Wednesday?
Benzinga · 12/23/2025 18:18
What's Going On With BioMarin Stock On Tuesday?
Benzinga · 12/23/2025 18:05
BridgeBio Has More Room To Run
Seeking Alpha · 12/23/2025 17:41
BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know
Barchart · 12/23/2025 14:00
BioMarin Pharmaceutical Price Target Raised to $100.00/Share From $80.00 by Truist Securities
Dow Jones · 12/23/2025 13:19
BioMarin Pharmaceutical Is Maintained at Buy by Truist Securities
Dow Jones · 12/23/2025 13:19
BUZZ-Oppenheimer starts Spruce Biosciences with "outperform" rating on rare disease strength 
Reuters · 12/23/2025 13:12
Truist Securities Maintains Buy on BioMarin Pharmaceutical, Raises Price Target to $100
Benzinga · 12/23/2025 13:08
BioMarin price target raised to $100 from $80 at Truist
TipRanks · 12/23/2025 12:40
Truist Financial Sticks to Their Buy Rating for BioMarin Pharmaceutical (BMRN)
TipRanks · 12/23/2025 12:16
BIOMARIN PHARMACEUTICAL INC <BMRN.O>: TRUIST SECURITIES RAISES TARGET PRICE TO $100 FROM $80
Reuters · 12/23/2025 11:55
Spruce Biosciences initiated with an Outperform at Oppenheimer
TipRanks · 12/23/2025 11:30
U.S. RESEARCH ROUNDUP-APi Group, Elf Beauty, Tesla
Reuters · 12/23/2025 07:05
BioMarin: Amicus Buyout Sparks My Enthusiasm
Seeking Alpha · 12/22/2025 20:15
More
Webull provides a variety of real-time BMRN stock news. You can receive the latest news about Biomarin Pharmaceutical Inc through multiple platforms. This information may help you make smarter investment decisions.
About BMRN
BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.